A contrast agent used during radiology scans is legally a device and not a drug, the DC Circuit Court of Appeals determined on 16 April in a rebuke to the US Food and Drug Administration.
The ruling marked a victory for Genus Medical Technologies, who sued the FDA in 2019 after the agency determined that its barium sulfate products, which are sold under the brand name Vanilla SilQ, should be regulated as drugs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?